BCL2 and B-cell chronic lymphocytic leukemia: ABT-199 (Venetoclax) is the first Bcl-2 inhibitor approved by FDA for the treatment of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML) (Cang et al., 2015; Deeks, 2016).